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Receptor–Related Protein 1 Reverses Cartilage Matrix
Degradation in Osteoarthritis
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Linda Troeberg,1 Yoshifumi Itoh,1 Gillian Murphy,2 and Hideaki Nagase1
Objective. The aggrecanase ADAMTS-5 and the
collagenase matrix metalloproteinase 13 (MMP-13) are
constitutively secreted by chondrocytes in normal carti-
lage, but rapidly endocytosed via the cell surface endocytic
receptor low-density lipoprotein receptor–related protein
1 (LRP-1) and subsequently degraded. This endocytic sys-
tem is impaired in osteoarthritic (OA) cartilage due to
increased ectodomain shedding of LRP-1. The aim of this
study was to identify the LRP-1 sheddase(s) in human
cartilage and to test whether inhibition of LRP-1 shedding
prevents cartilage degradation in OA.
Methods. Cell-associated LRP-1 and soluble LRP-
1 (sLRP-1) released from human cartilage explants and
chondrocytes were measured by Western blot analysis.
LRP-1 sheddases were identified by proteinase inhibitor
profiling and gene silencing with small interfering RNAs.
Specific monoclonal antibodies were used to selectively
inhibit the sheddases. Degradation of aggrecan and colla-
gen in human OA cartilage was measured by Western
blot analysis using an antibody against an aggrecan
neoepitope and a hydroxyproline assay, respectively.
Results. Shedding of LRP-1 was increased in OA
cartilage compared with normal tissue. Shed sLRP-1
bound to ADAMTS-5 and MMP-13 and prevented their
endocytosis without interfering with their proteolytic activ-
ities. Two membrane-bound metalloproteinases, ADAM-
17 and MMP-14, were identified as the LRP-1 sheddases
in cartilage. Inhibition of their activities restored the
endocytic capacity of chondrocytes and reduced degrada-
tion of aggrecan and collagen in OA cartilage.
Conclusion. Shedding of LRP-1 is a key link to OA
progression. Local inhibition of LRP-1 sheddase activities
of ADAM-17 and MMP-14 is a unique way to reverse
matrix degradation in OA cartilage and could be effective
as a therapeutic approach.
Osteoarthritis (OA) is the most prevalent age-
related joint disorder, but there is no disease-modifying
treatment available except for joint replacement surgery (1).
Themain cause of the disease is degradation of articular car-
tilage due to elevated activities of matrix metalloproteinases
(MMPs) and ADAMTS. While both ADAMTS-4 and
ADAMTS-5 have been considered to participate in aggre-
can degradation in human OA (2,3), recent studies by
Larkin et al with neutralizing monoclonal antibodies have
shown that ADAMTS-5 is more effective than ADAMTS-4
in aggrecan degradation in humanOA cartilage and nonhu-
man primates in vivo (4). Collagen fibrils are mainly
degraded by collagenolytic MMPs, and MMP-13 is consid-
ered to be themajor collagenase inOA cartilage (5–7).
We have recently found that both ADAMTS-5 and
MMP-13 are constitutively produced in healthy human car-
tilage, but they are rapidly taken up by the chondrocytes via
the endocytic receptor low-density lipoprotein receptor–
related protein 1 (LRP-1) and degraded intracellularly
(8–10). These findings suggest that they probably function
for a very short period of time to maintain normal
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homeostatic turnover of extracellular matrix (ECM) com-
ponents of the tissue. Other proteins that are endocytosed
by LRP-1 include ADAMTS-4 (11) and tissue inhibitor of
metalloproteinases 3 (TIMP-3) (12,13), indicating that
LRP-1 is a key modulator of cartilage matrix degradation
systems. This endocytic pathway is impaired in OA carti-
lage because of the reduction of protein levels of LRP-1 in
chondrocytes without any significant changes in the level of
messenger RNA (mRNA) for LRP-1, resulting in
increased extracellular activity of ADAMTS-5 (8). We thus
proposed that the loss of LRP-1 in OA cartilage is due to
proteolytic shedding of the receptor, and that this process
shifts normal homeostatic conditions of cartilage to a more
catabolic environment, leading to the development ofOA.
The aim of this study was to identify the
“sheddase” activities that cleave LRP-1 and release the
soluble form of LRP-1 (sLRP-1) in human cartilage. We
also aimed to test whether inhibition of the sheddase(s)
prevents the degradation of cartilage in OA.
MATERIALS AND METHODS
Reagents and antibodies. The sources of materials
used were as follows: mouse monoclonal anti–LRP-1 a-chain
antibody (8G1), mouse anti–LRP-1 b-chain monoclonal anti-
body (5A6) that recognizes the ectodomain, BC-3 mouse mono-
clonal antibody that recognizes the N-terminal 374ARGSV
aggrecan core protein fragments generated by aggrecanase, rab-
bit anti–ADAM-10 polyclonal antibody (ab1997), rabbit anti–
ADAM-17 polyclonal antibody (ab2051), and rabbit anti–MMP-
14 monoclonal antibody (ab51074) were from Abcam; mouse
anti–FLAG M2 monoclonal antibody, chondroitinase ABC,
endo-b-galactosidase, bovine nasal septum type II collagen, E-
64, and 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF)
were from Sigma; human recombinant interleukin-1a (IL-1a)
and tumor necrosis factor (TNF) were from PeproTech; rabbit
antitubulin polyclonal antibody (no. 2148) was from Cell Signal-
ing Technology; goat antiactin polyclonal antibody (I-19) was
from Santa Cruz Biotechnology; human plasma IgG (1-001-A)
was from R&D Systems; solubilized and purified full-length
human LRP-1 was from BioMac; and a hydroxamate-based
MMP inhibitor, CT1746, was fromUCB Celltech.
Anti-human ADAMTS-5 catalytic domain rabbit poly-
clonal antibody was raised in rabbits and characterized (14).
Inhibitory monoclonal antibodies against human ADAM-17
(D1A12) (15), MMP-14 (E2C6), desmin (negative control anti-
body) (16), and ADAMTS-5 (2D3) (9); bovine nasal aggrecan
(17), receptor-associated protein (RAP) (8), recombinant human
ADAMTS-5 lacking the C-terminus thrombospondin domain
with a FLAG tag at the C-terminus (14), MMP-13 with a FLAG
tag between the signal and propeptide (18), TIMP-1 (19), TIMP-
2 (20), TIMP-3 (21), and N-terminal domain of human TIMP-3
(22) were prepared as described previously. All other reagents
used were of the highest available analytic grade.
Human cartilage tissue preparation and isolation of
chondrocytes. Cartilage from femoral condyles of human knee
joints was used. Healthy normal articular cartilage was obtained
from patients following knee amputation due to soft tissue
sarcoma or osteosarcoma with no involvement of the cartilage.
Tissue specimens were obtained from 9 patients (6 males, ages
9–57 years, mean age 35.5 years; 3 females, ages 13–19 years,
mean age 15.7 years). Human OA articular cartilage was
obtained from patients following total knee replacement surgery.
Tissues were obtained from 16 patients (8 males, ages 51–86
years, mean age 75.1 years; 8 females, ages 50–82 years, mean
age 68.1 years). Dissected cartilage (;18 mm3, ;20 mg wet
weight/piece) was placed in one well of a round-bottomed 96-
well plate and allowed to rest for 24 hours in 200 ml of Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS) before use. The medium was replaced, and the car-
tilage was rested for a further 24–96 hours in 200 ml of DMEM
at 378C before the assays were performed. Chondrocytes were
isolated as described previously (12). Primary chondrocytes were
used in the experiments to compare normal and OA chondro-
cytes, and passaged cells were used in the experiments to identify
the LRP-1 sheddase.
Western blot analysis of LRP-1 in cartilage. To ana-
lyze LRP-1 in the cartilage, medium was removed after incuba-
tion for various periods of time, and then total protein was
extracted by adding 50 ml of 43 sodium dodecyl sulfate (SDS)
sampling buffer (200 mM Tris HCl [pH 6.8]/8% SDS and 20%
glycerol) to each explant in a 96-well plate. After 1 hour of incu-
bation, the sample buffers were pooled from each condition (3
explants per condition), and 10 ml of samples was analyzed by
SDS–polyacrylamide gel electrophoresis (PAGE) under nonre-
ducing conditions and Western blotting using anti–LRP-1 a-
chain, anti–LRP-1 b-chain, and antitubulin antibodies. Immune
signals of LRP-1 and tubulin were quantified using ImageJ soft-
ware (National Institutes of Health), and the relative amounts of
LRP-1 a- and b-chains in the cartilage extracts were estimated
using tubulin as an internal control.
Immunofluorescence staining of LRP-1. OA and nor-
mal cartilage samples (n5 3 each) were rested in culture with
DMEM for 2 days. Explants were then snap-frozen and
sectioned (5-mm sections) using a CM1900 cryostat (Leica
Microsystems). Each sample was fixed with methanol and incu-
bated with anti–LRP-1 b-chain antibody for 3 hours at room
temperature. Incubation with Alexa Fluor 568–conjugated anti-
mouse IgG (Molecular Probes) for 1 hour at room temperature
was used to visualize the antigen signals. Nuclei were stained
with DAPI. Samples were viewed using an Eclipse TE2000-U
confocal laser scanning microscope (Nikon). Data were collated
using Volocity software (Improvision).
Quantitative reverse transcriptase–polymerase chain
reaction (qRT-PCR). Quantitative RT-PCR was carried out as
described previously (8). Briefly, RNA was extracted and isolated
from 50 mg of ground cartilage tissue using an RNeasy kit
(Qiagen), and complementary DNA was then generated using a
reverse transcription kit following the guidelines of the manufac-
turer (Applied Biosystems). Complementary DNA was then
used for real-time PCR assays using TaqMan technology. The
DDCt method of relative quantitation was used to calculate rela-
tive mRNA levels for each transcript examined. The 60S acidic
ribosomal protein P0 (RPLP0) gene was used to normalize the
data. Predeveloped primer/probe sets for LRP-1, ADAM-12,
and RPLP0 were purchased from Applied Biosystems.
Western blot analysis of cellular LRP-1 and sLRP-1.
Chondrocytes (5 3 104) were cultured in 12-well plates in 2 ml
of DMEM containing 10% FCS for 2 days. Cells were rested
in 1 ml of DMEM for 24 hours, and the medium was replaced
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with 1 ml of DMEM and used in the experiments. After incu-
bation for various periods of time, the medium was collected
and concentrated 20-fold using spin filters (Microcon YM-30;
Merck Millipore), and 20 ml of 43 SDS sampling buffer was
added to 50 ml of each concentrated medium. The cells were
lysed with 200 ml of 23 SDS sampling buffer, and 10 ml of sam-
ples were analyzed by SDS-PAGE under nonreducing conditions
and Western blotting using anti–LRP-1 a-chain, anti–LRP-1 b-
chain, and antitubulin antibodies. Immune signals of LRP-1 and
tubulin were quantified using ImageJ software, and the relative
amounts of LRP-1 a-chain in the medium and LRP-1 a- and b-
chains in the cell lysate were estimated within the linear range of
measurements (see Supplementary Figures 1A and B, available
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40080/abstract) and normalized using
tubulin, and those in the standard cell lysates of chondrocytes
were used as internal controls. An absolute number of LRP-1
molecules released into medium was estimated by comparing
various concentrations of purified LRP-1 within a reasonable
linear range.
Flow cytometric analysis of LRP-1. Cells were plated
in 6-well plates in DMEM containing 10% FCS and incubated
until 80% confluent. Cells were rested in 2 ml of DMEM for 1
day, detached using a cell scraper, and fixed for 5 minutes at 48C
with ice-cold methanol followed by 2 washes with fluorescence-
activated cell sorting (FACS) buffer (phosphate buffered saline
containing 5% goat serum and 3% bovine serum albumin
[BSA]). Cells were stained for 30 minutes at 258C with anti–
LRP-1 b-chain antibody, washed with FACS buffer, and then
further incubated with allophycocyanin-conjugated goat anti-
mouse IgG (BD PharMingen) and isotype control in FACS
buffer for 20 minutes at 258C. Cells were then washed with
FACS buffer and analyzed using an LSRII flow cytometer (BD
Biosciences), and postacquisition data analysis was performed
using FlowJo software version 7.6.1 (Tree Star).
Analysis of endocytosis of ADAMTS-5 and MMP-13.
Cells (5 3 104) cultured in 24-well plates were rested in 500 ml
of DMEM for 1 day. The medium was replaced with 500 ml of
fresh DMEM with 10 nM of ADAMTS-5 or MMP-13 in the
absence or presence of 2 nM or 10 nM sLRP-1 or 500 nM RAP
at 378C. After incubation for 0–4 hours, media were collected
and the protein was precipitated with 5% trichloroacetic acid
and dissolved in 50 ml of 13 SDS sampling buffer containing
5% 2-mercaptoethanol. All samples were analyzed by SDS-
PAGE under reducing conditions and Western blotting using
anti–FLAGM2 antibody or anti–ADAMTS-5 antibody, respec-
tively. Immune signals for exogenously added ADAMTS-5 and
MMP-13 detected in the medium were quantified using ImageJ
software within the linear range of the measurements (see Sup-
plementary Figures 1C and D, http://onlinelibrary.wiley.com/
doi/10.1002/art.40080/abstract), and the amount of each recom-
binant protein remaining in the medium at each time point was
calculated as a percentage of the amount of each recombinant
protein at 0 hours.
Analysis of aggrecanolytic activity of ADAMTS-5.
Purified ADAMTS-5 (5 nM) was preincubated with 0–25 nM
purified sLRP-1 in TNCB buffer (50 mM Tris HCl [pH 7.5]/
150 mM NaCl/10 mM CaCl2/0.01% BSA) containing 0.01%
Brij-35 for 10 minutes at 258C. The mixture was diluted 100-
fold and incubated with 0.5 mg/ml purified bovine aggrecan
for 0–4 hours at 378C. The samples were deglycosylated as
described previously (23). Briefly, aggrecan was deglycosylated
in sodium acetate buffer with chondroitinase ABC and endo-
b-galactosidase (each 0.01 unit/100 mg of aggrecan) for
24 hours at 378C. Aggrecan was then precipitated using ice-
cold acetone and analyzed by Western blotting using the
antibody BC-3, which recognizes the N-terminal 374ARGSV
aggrecan core protein fragments generated by aggrecanase.
Small interfering RNA (siRNA)–mediated knockdown of
membrane-bound metalloproteinases. Small interfering RNA
oligonucleotides for ADAMs and MMP-14 (On-TargetPlus
SMARTpool siRNA) and nontargeting oligonucleotide were pur-
chased from Thermo Scientific Dharmacon. Cells were plated at a
density of 4 3 104 cells/well (12-well plate) in DMEM containing
10% FCS and incubated until 50% confluent. INTERFERin
(PeqLab) was used to transfect cells with siRNA at a final concen-
tration of 20 nM inOpti-MEM I (Gibco). After 48 hours of incuba-
tion, the medium was replaced with fresh DMEM with or without
10 ng/ml IL-1 or 200 ng/ml TNFand incubated further for 24 hours.
Cells were lysed with 200 ml of 23 SDS sampling buffer containing
5% 2-mercaptoethanol, and then the samples were analyzed by
SDS-PAGE under reducing conditions andWestern blotting using
anti–ADAM-10, anti–ADAM-17, anti–MMP-14, and antiactin
antibodies. Immune signals of each enzyme and actin were quanti-
fied using ImageJ software, and the relative amount of each enzyme
was estimated using actin as an internal control.
Analysis of the effect of inhibitory antibodies against
ADAM-17 and MMP-14 on LRP-1 protein levels. Normal
chondrocytes (5 3 104) cultured in 24-well plates were rested in
500 ml of DMEM for 1 day. The medium was replaced with 500
ml of fresh DMEM with or without 10 ng/ml IL-1 in the absence
or presence of various concentrations of combinations of the
control antibodies (human IgG for the anti–ADAM-17 antibody
[D1A12] and antidesmin intracellular domain antibody for the
anti–MMP-14 antibody [E2C6]) or the anti–ADAM-17 and the
anti–MMP-14 antibodies. After 24 hours of incubation, the cells
were lysed with 100 ml of 23 SDS sampling buffer, and then
LRP-1 a- and b-chains were detected as described above. To
test the effect of inhibitory antibodies against ADAM-17 and
MMP-14 on LRP-1 levels in OA chondrocytes and cartilage in
culture, cells and cartilage explants were cultured for 24 hours
with DMEM in the absence or presence of combinations of 250
nM each of the control antibodies, the anti–ADAM-17 antibody
and the antidesmin antibody, the anti–MMP-14 antibody and
IgG, or the anti–ADAM-17 and the anti–MMP-14 antibodies.
LRP-1 a- and b-chains were then detected as described above.
Analysis of aggrecan degradation in OA cartilage.
OA cartilage was cultured in a round-bottomed 96-well plate (1
explant per well) and rested in DMEM for 1 day. The cartilage
was further cultured in DMEM in the absence or presence of a
combination of 2 antibodies (250 nM each) (i.e., combination of
the anti–ADAM-17 antibody and the antidesmin antibody [con-
trol], combination of the anti–MMP-14 antibody and IgG [con-
trol], combination of the anti–ADAM-17 and the anti–MMP-14
antibodies, or combination of the antidesmin antibody and IgG),
or 250 nM of anti–ADAMTS-5 or N-terminal domain of human
TIMP-3. After 12 hours of incubation, the medium was replaced
with fresh DMEM containing the antibodies or TIMP and incu-
bated further for 0–48 hours. For Western blotting, the condi-
tioned media were pooled from each condition (3 explants per
condition) and deglycosylated as described above, and immunore-
activity was measured within the linear range of the assay based
on standard samples (see Supplementary Figure 1E, http://
onlinelibrary.wiley.com/doi/10.1002/art.40080/abstract).
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Analysis of collagen degradation in OA cartilage.
OA cartilage was cultured with various antibodies or with 250 nM
of TIMP-1 as described above for aggrecan degradation studies,
and media were harvested after 96 hours. The extent of type II
collagen degradation in OA cartilage was assessed by measuring
the amount of hydroxyproline released into the media using a
modification of the assay described by Bergman and Loxley (24).
The hydroxyproline contents in cartilage explant remnants after
culture were also determined by digesting them in 500 ml of
papain digest solution (0.05M phosphate buffer [pH 6.5]/2 mM
N-acetylcysteine/2 mM EDTA/10 mg/ml papain) at 658C for 24
hours. The relative amount of collagen degradation was esti-
mated by dividing the amount of hydroxyproline released into the
medium by the summed amount of hydroxyproline in the
medium and in the papain digests.
Study approval. Normal human articular cartilage tis-
sue specimens were obtained from the Stanmore BioBank, Insti-
tute of Orthopaedics, Royal National Orthopaedic Hospital,
Stanmore, following informed consent from patients and
approval by the Royal Veterinary College Ethics and Welfare
Committee (Institutional approval Unique Reference Number
2012 0048H). Human OA cartilage tissue specimens were
obtained from the Oxford Musculoskeletal Biobank and were
collected with informed donor consent in full compliance with
national and institutional ethical requirements, the United King-
dom Human Tissue Act, and the Declaration of Helsinki
A
E
DB
α-chain
1 2 3 4 5 6 1 2 3 4 5
Normal OA
117
71
460
268
(kDa)
6
Human knee cartilage explants
β-chain
Tubulin
460
268
171
117
C
el
l l
ys
at
e
(kDa)
M
ed
iu
m
117
71
55
Std 24 48 24 48
Normal
(h)
OA
460
268
171
117
α-chain
β-chain
Tubulin
α-chain
F
C
*
Normal OA
0.0
0.5
1.0
1.5
C
el
lu
la
r L
R
P1
 
-c
ha
in
 (r
el
at
iv
e)
Flow cytometry
α-chain
*
β-chain
**
Normal OA Normal OA
0.0
0.5
1.0
1.5
2.0
LR
P1
 in
 c
ar
tila
ge
 (r
el
at
iv
e)
Cell lysate Medium
Normal OA
*
(h)
Normal OA
**
*
*
24 48 24 48 24 48 24 48
0.0
0.5
1.0
1.5
2.0
LR
P1
 
-c
ha
in
 (r
el
at
iv
e)
H I
Normal OA
Br
ig
ht
 fi
el
d
D
AP
I
LR
P1
 β-
ch
ai
n
Normal OA
0
1
2
3
LR
P1
 m
R
N
A 
(r
el
at
iv
e)
G
0 1 2 4 1 2 4
Normal OA
1 2 4 1 2 4 1 2 4 (h)
ADAMTS-5 
alone Normal OA
RAP
95
(kDa)
72
ADAMTS-5 *
*
0 1 2 3 4
0
25
50
75
100
Incubation time (h)
AD
AM
TS
-5
 in
 m
ed
iu
m
 (%
)
Normal
OA
Normal/RAP
OA/RAP
Figure 1. Increased ectodomain shedding of low-density lipoprotein receptor–related protein 1 (LRP-1) and reduced endocytic capacity of chondro-
cytes in human osteoarthritic (OA) cartilage. A, Western blotting of total proteins extracted from cartilage explants of human knee joints of OA patients
and patients without arthritis (n5 6 each) with antibodies against a- and b-chains of LRP-1. B, Densitometric analysis of LRP-1 in A. Data were nor-
malized against tubulin. C, Immunofluorescence staining of LRP-1 in frozen section of human knee cartilage. Dotted lines indicate the articular cartilage
surface. Bar5 100 mm. D, Relative levels of mRNA for LRP-1 in cartilage, measured by TaqMan quantitative reverse transcriptase–polymerase chain
reaction. E, Representative Western blotting of LRP-1 protein in cell lysates and medium of human normal and OA chondrocytes (n5 6 donors each).
Std5 standard cell lysates. F, Quantification of LRP-1 a-chain detected in E. G, Flow cytometric analysis of LRP-1 b-chain. H, Representative Western
blotting for endocytosis of ADAMTS-5 (10 nM) by human normal and OA chondrocytes (n5 3 donors each) with or without the LRP-1 ligand antago-
nist receptor-associated protein (RAP) (500 nM). ADAMTS-5 in the medium was detected by Western blotting using anti–ADAMTS-5 antibody. I,
Quantification of findings in H. In B, D, F, and G, symbols represent individual cartilage donors; bars show the mean6 SD. The mean values in normal
cartilage and chondrocytes were set at 1 (dashed lines). In I, values are the mean6 SD. *5P, 0.05; **5P, 0.01, by Student’s 2-tailed t-test.
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(Human Tissue Authority Licence 12217 and Oxford Research
Ethics Committee C 09/H0606/11).
Statistical analysis. All quantified data are represented
as the mean6SD where applicable. Significant differences be-
tween data sets were determined using Student’s 2-tailed t-test
or one-way analysis of variance followed by Dunnett’s multiple
comparison test, where indicated.
RESULTS
Increased ectodomain shedding of LRP-1 and re-
duced endocytic capacity in human OA cartilage. We first
verified the loss of LRP-1 protein in human OA cartilage.
LRP-1 consists of an extracellular 515-kd a-chain and an
85-kd b-chain that are processed from the precursor by
furin. The a-chain contains the ligand-binding domains,
and the b-chain has an extracellular domain, a transmem-
brane domain, and a cytoplasmic domain. Western blot-
ting analyses of a- and b-chains of cartilage extracts with
antibodies that recognize the N-terminus of the a-chain
and the extracellular domain of the b-chain showed that
both chains were reduced in OA cartilage by ;48% and
;65%, respectively, compared with normal cartilage (Fig-
ures 1A and B). The reduction of LRP-1 was further con-
firmed by immunofluorescence staining of b-chain in the
cartilage (Figure 1C). No significant change in the level of
mRNA for LRP-1 between normal and OA cartilage (Fig-
ure 1D) suggested that the loss of LRP-1 in OA cartilage
was due to proteolytic shedding of the receptor.
To further investigate the increased shedding of
LRP-1 in OA cartilage, chondrocytes were cultured and
LRP-1 proteins were analyzed. Both a- and b-chains were
reduced in OA cell lysates compared with normal chondro-
cytes, which was accompanied by an increased release of full-
length a-chain into the medium (Figures 1E and F). Flow
cytometric analysis of the b-chain with antiectodomain anti-
body further confirmed the reduction of cell surface LRP-1
including the b-chain in OA chondrocytes (Figure 1G), sug-
gesting that the primary shedding site is located in the ecto-
domain of the b-chain. We estimated that a single normal
chondrocyte released ;3.96 2.7 3 103 LRP-1 molecules
per hour (mean6 SD), while a single OA chondrocyte
released 9.66 5.43 103LRP-1molecules per hour.As antic-
ipated, the endocytic capacity of human OA chondrocytes
was significantly reduced; the half-life of ADAMTS-5 was
;2.8-fold longer in OA chondrocytes (;210 minutes) than
in normal chondrocytes (;75minutes) (Figures 1H and I).
Soluble LRP-1 ectodomain prevents endocytosis
of ADAMTS-5 and MMP-13 without interfering with
their activities. We then evaluated whether sLRP-1 alters
half-lives of cartilage-degrading metalloproteinases. As
shown in Figures 2A andB, endocytosis of ADAMTS-5 and
MMP-13 was reduced partially with 2 nM sLRP-1 and
almost completely inhibited with 10 nM sLRP-1 to the level
that was attained with the LRP ligand antagonist RAP. We
also found that sLRP-1–bound ADAMTS-5 and MMP-13
retained activity against their natural substrates, aggrecan
and collagen, respectively (Figures 2C and D). It is notable
thatADAMTS-5 bound to sLRP-1was;3-foldmore active
on aggrecan cleavage comparedwith freeADAMTS-5 (Fig-
ure 2C). Thus, shedding of the LRP-1 ectodomain impairs
the endocytic capacity of the cell not only by reducing the
level of cell surface LRP-1 but also by converting
membrane-anchored LRP-1 into soluble decoy receptors,
leaving excessmatrix-degrading proteinases extracellularly.
ADAM-17 and MMP-14 are responsible for shed-
ding LRP-1 in human chondrocytes. To identify the LRP-
1 sheddase in human chondrocytes, we first examined
whether proinflammatory cytokines such as IL-1 and TNF
that stimulate cartilage matrix degradation increase LRP-1
shedding, as this might facilitate characterization of the
sheddase in the cartilage. As shown in Figures 3A–C, these
cytokines increased LRP-1 shedding ;4.0-fold in normal
human chondrocytes. The cytokine-stimulated LRP-1 shed-
ding was inhibited by the hydroxamate metalloproteinases
inhibitor CT1746, but not by a serine proteinase inhibitor
(AEBSF) or a cysteine proteinase inhibitor (E-64) (Figure
3D). Among the 3 TIMPs tested, TIMP-1 was not effective
but TIMP-2 and TIMP-3 were, and TIMP-3 showed the
strongest inhibition (Figure 3E). Thus, we postulated that the
responsible enzyme was likely to be a membrane-anchored
ADAMorMMP.
ADAM-10, ADAM-12, ADAM-17, and MMP-14
have previously been reported to be LRP-1 sheddases in
other cell types (25). We therefore ablated each enzyme
individually using a specific siRNA. The ADAM-10 pro-
tein level was reduced by ;90%, and the ADAM-12
mRNA level was reduced by ;88% (see Supplementary
Figures 2A–C, http://onlinelibrary.wiley.com/doi/10.1002/
art.40080/abstract), but their knockdown did not affect
LRP-1 shedding (see Supplementary Figure 2D). Small
interfering RNAs targeting ADAM-17 and MMP-14
reduced their protein levels by 76% and 84%, respectively
(see Supplementary Figures 2E and F), and knockdown
of each partially inhibited LRP-1 shedding (Figure 3F).
However, knockdown of both MMP-14 and ADAM-17
exhibited a stronger, additive effect, to the level achieved by
TIMP-3 (Figure 3F), which suggests that these 2 proteinases
function as LRP-1 sheddases. A low level of LRP-1 shedding
occurred in unstimulated chondrocytes, and was mainly due
toMMP-14.
Combination of inhibitory antibodies against
ADAM-17 and MMP-14 blocks LRP-1 shedding in OA
cartilage. To verify the role of ADAM-17 and MMP-14
in LRP-1 shedding, we used the recently developed
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specific antibodies against ADAM-17 (D1A12) (15) and
against MMP-14 (E2C6) (16), which inhibit the target
enzymes with inhibition constants of 0.46 nM and 0.11
nM, respectively. The IL-1–induced loss of LRP-1 was
partially inhibited by a single antibody, but a combination
of the 2 antibodies blocked LRP-1 shedding to the level of
IL-1–untreated cells (Figure 4A). They were similarly
effective at blocking LRP-1 shedding in OA chondrocytes
(Figure 4B). The anti–MMP-14 antibody increased cellu-
lar levels of the LRP-1 a- and b-chains 1.6-fold and 2.1-
fold, respectively, while the anti–ADAM-17 antibody
increased them 1.4-fold and 1.8-fold, respectively. A com-
bination of the 2 antibodies increased both a- and b-
chains 2.3-fold and 2.6-fold, respectively (Figure 4B). The
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Figure 2. Ectodomain of soluble low-density lipoprotein receptor–related protein 1 (sLRP-1) prevents endocytosis of ADAMTS-5 and matrix
metalloproteinase 13 (MMP-13) without interfering with their activities. A and B, Normal human chondrocytes (n5 3 donors) were cultured
with Dulbecco’s modified Eagle’s medium containing 10 nM ADAMTS-5 (A) or 10 nM MMP-13 (B) with no additional treatment (Control) or
in the presence of 2 nM sLRP-1, 10 nM sLRP-1, or 500 nM receptor-associated protein (RAP) for 0–4 hours. ADAMTS-5 and MMP-13 in the
medium were detected by Western blotting using anti–FLAG M2 antibody. Top, Representative Western blotting. Bottom, Quantification of
findings in Western blotting. C, Bovine aggrecan (0.5 mg/ml) was incubated with 0.05 nM ADAMTS-5 alone (1:0) or in the presence of 0.05 nM
sLRP-1 (1:1) or 0.25 nM sLRP-1 (1:5) for 1–4 hours at 378C. The reactions were stopped with 10 mM EDTA, and the reaction products were
deglycosylated and subjected to Western blotting using antibody against the aggrecan neoepitope 374ARGSV (ARGS). Top, Representative
Western blotting. Bottom, Quantification of findings in Western blotting. D, Type II collagen (1 mg/ml) was incubated with 5 nM MMP-13 alone
(1:0) or in the presence of 5 nM sLRP-1 (1:1) or 25 nM sLRP-1 (1:5) for 1–3 hours at 258C. The reactions were stopped with 10 mM EDTA,
and the reaction products were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie brilliant
blue staining. Top, Representative SDS-PAGE. Bottom, Quantification of findings in SDS-PAGE. In C and D, the mean values after 1 hour of
incubation without sLRP-1 were set at 1 (dashed lines). Values are the mean6 SD. *5P, 0.05; ****5P, 0.0001, by Student’s 2-tailed t-test
(A and B) or one-way analysis of variance followed by Dunnett’s multiple comparison test (C).
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restoration of LRP-1 in OA chondrocytes by combining
the 2 antibodies was time dependent, and it reached a pla-
teau at 24 hours (Figure 4C). Addition of the 2 antibodies
to OA cartilage blocked LRP-1 shedding and increased a-
and b-chains 2.6-fold and 2.3-fold, respectively (Figure
4D). This indicates that the antibodies can penetrate the
tissue and inhibit the LRP-1 sheddases in OA cartilage.
Blocking of LRP-1 sheddases restores endocytic
capacity and reduces the degradation of aggrecan and
collagen in OA cartilage. We then tested the effect of
combining the 2 antibodies on the endocytic capacity of
OA chondrocytes. The antibody-treated OA chondro-
cytes cleared exogenously added ADAMTS-5 from the
medium;2.4-fold faster (half-life;95 minutes) than the
untreated OA chondrocytes (half-life ;210 minutes)
(Figure 5A), indicating that blocking LRP-1 sheddases
restored the endocytic capacity of OA chondrocytes close
to that of normal chondrocytes.
Remarkably, combined antibody treatment re-
duced the degradation of aggrecan and collagen in OA
cartilage. Analysis of the same conditioned media for
the aggrecanase-specific cleavage motif using the anti-
body against the 374ARGSV neoepitope indicated that
aggrecanase activity was markedly inhibited by blocking
LRP-1 sheddases (Figure 5B) (see Supplementary Figure
3, http://onlinelibrary.wiley.com/doi/10.1002/art.40080/
abstract). Potent inhibition with the anti–ADAMTS-
5 antibody and TIMP-3 indicated that the primary
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Figure 3. ADAM-17 and matrix metalloproteinase 14 (MMP-14) are the responsible sheddases of low-density lipoprotein receptor–related protein 1
(LRP-1) in human chondrocytes. A, Results of culturing human normal chondrocytes (n5 3 donors) with Dulbecco’s modified Eagle’s medium in the
presence or absence of 10 ng/ml interleukin-1 (IL-1) or 200 ng/ml tumor necrosis factor (TNF) for 8–48 hours. LRP-1 proteins in the cell lysate and
the medium were analyzed by Western blotting with antibodies against a- and b-chains of LRP-1. B and C, Quantification of LRP-1 protein in the
cell lysate (B) and soluble LRP-1 (sLRP-1) released into the medium (C) with or without IL-1 or TNF treatment. D, Effect of the metalloproteinase
inhibitor CT1746 (20 mM), the serine proteinase inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) (50 mM), or the cysteine proteinase inhib-
itor E-64 (10 mM) on cytokine-induced LRP-1 shedding with or without IL-1 or TNF treatment. E, Effect of tissue inhibitor of metalloproteinases 1
(TIMP-1) (500 nM), TIMP-2 (500 nM), or TIMP-3 (300 nM) on cytokine-induced LRP-1 shedding with or without IL-1 or TNF treatment. F, Effect
of small interfering RNA (siRNA)–mediated knockdown of ADAM-17 and/or MMP-14 on cytokine-induced LRP-1 shedding with or without IL-1 or
TNF treatment. Values in B–F are the mean6 SD. In B–D, the mean values in the cells incubated without cytokine for 8 hours (B) or 24 hours (C
and D) were set at 1 (dashed lines). In E and F, the mean values in the cells transfected with nontargeting siRNA were set at 1 (dashed lines).
*5P, 0.05; **5P, 0.002; ***5P, 0.0002; ****5P, 0.0001, by one-way analysis of variance followed by Dunnett’s multiple comparison test.
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aggrecanase in OA cartilage was ADAMTS-5. Effective
inhibition of aggrecan degradation by the combination of
anti–ADAM-17 and anti–MMP-14 antibodies was further
confirmed by Safranin O staining of the cartilage (see Sup-
plementary Figure 4, http://onlinelibrary.wiley.com/doi/10.
1002/art.40080/abstract).
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Figure 4. Combination of antibodies inhibiting ADAM-17 and matrix metalloproteinase 14 (MMP-14) blocks shedding of low-density lipoprotein
receptor–related protein 1 (LRP-1) in osteoarthritic (OA) cartilage. A, Results of culturing human normal chondrocytes (n5 3 donors) with
Dulbecco’s modified Eagle’s medium without (None) or with 10 ng/ml interleukin-1 (IL-1) in the absence or presence of combined anti–ADAM-17
and anti–MMP-14 (10–200 nM each) for 48 hours. LRP-1 proteins in the cell lysate were analyzed by Western blotting with antibodies against a-
and b-chains of LRP-1. B, Effect of combining anti–MMP-14 and anti–ADAM-17 antibodies (200 nM each) on LRP-1 shedding in human OA chon-
drocytes (n5 5 donors). C, Time course analysis of the effect of combined anti–MMP-14 and anti–ADAM-17 antibodies on the recovery of cellular
LRP-1. D, Effect of combined anti–MMP-14 and anti–ADAM-17 antibodies on LRP-1 shedding in human knee OA cartilage explants (n5 6 donors
each). In A, values are the mean6 SD, and the mean value in the cells incubated without IL-1 or the antibodies was set at 1 (dashed line). In B–D,
symbols represent individual cartilage donors; bars show the mean6 SD. In B–D, the mean values in the cells or cartilage incubated with the control
antibodies for 8 hours (C) or 24 hours (B and D) were set at 1 (dashed lines). *5P, 0.05, by Student’s 2-tailed t-test.
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Figure 5. Blocking of low-density lipoprotein receptor–related protein 1 (LRP-1) sheddases restores endocytic capacity and reduces aggrecan
and collagen degradation in osteoarthritic (OA) cartilage. A, Recovery of endocytic capacity in OA chondrocytes upon treatment with anti–
ADAM-17 and anti–matrix metalloproteinase 14 (anti–MMP-14) antibodies (Ab). Endocytosis of ADAMTS-5 (10 nM) was measured as
described in Figures 1H and I (n5 3 donors). B and C, Inhibition of aggrecan and collagen degradation in human OA cartilage upon treatment
with combined anti–ADAM-17 and anti–MMP-14 antibodies. OA knee cartilage explants were incubated with antibodies or tissue inhibitor of
metalloproteinases (TIMP) at 250 nM. B, Aggrecan degradation detected after 48 hours with an antibody against the aggrecan neoepitope
374ARGSV. The mean value in medium of the cartilage incubated with the control antibodies was set at 100 (dashed line) (n5 8 donors). C,
Collagen degradation of cultured OA cartilage after 96 hours of incubation, measured by hydroxyproline assay. The amount of hydroxyproline
released with control antibodies was set at 100 (dashed line). In A, values are the mean6 SD. In B and C, symbols represent individual cartilage
donors; bars show the mean6SD. The mean values in media of the cartilage incubated with the control antibodies for 48 hours (B) or 96 hours
(C) were set at 100 (dashed lines). *5P, 0.05, by Student’s 2-tailed t-test (A) or one-way analysis of variance followed by Dunnett’s multiple
comparison test (C). RAP5 receptor-associated protein; N-TIMP-35N-terminal domain of human TIMP-3.
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Collagen degradation was also inhibited in the
presence of anti–ADAM-17 and anti–MMP-14 antibodies
by 5% and 10%, respectively, and more effective inhibi-
tion (17%) was observed upon combining the 2 antibodies
(Figure 5C). In general, anti–MMP-14 showed a stronger
effect than anti–ADAM-17, but there was considerable
patient-to-patient variation in the effect of each antibody,
which may reflect the multifactorial nature of OA. Inhibi-
tion was also detected with TIMP-1 treatment, but not
with the anti–ADAMTS-5 antibody, indicating that colla-
gen degradation is specific to collagenase. Cell viability
analysis indicated that none of these treatments was toxic
to chondrocytes (data not shown).
DISCUSSION
In this study, we have shown that the ectodomain
shedding of LRP-1 may be an important regulator of the
development of human OA. The specific inhibitory anti-
bodies that we recently developed for humanMMP-14 and
ADAM-17 have allowed us to evaluate the role of LRP-1
shedding in degradation of cartilage matrix in human sub-
jects and thus provided clinically relevant information.
Numerous membrane-anchored proteins are re-
leased from the cell surface by the process of regulated pro-
teolysis called ectodomain shedding, and the enzymes
responsible for shedding are primarily membrane-anchored
proteinases. This process regulates a wide variety of cellular
and physiologic functions, and dysregulated shedding is
linked to numerous diseases, such as Alzheimer’s disease,
inflammation, rheumatoid arthritis (RA), cancer, chronic
kidney disease, cardiac hypertrophy, and heart failure
(26,27). LRP-1 shedding is increased under inflammatory
conditions such as in RA and systemic lupus erythematosus
(28), and in cancer (29,30), but the exact pathologic role of
LRP-1 shedding in these diseases has not been clearly under-
stood.We propose that LRP-1 shedding in local tissues under
inflammatory or chronic pathologic conditions dysregulates
normal turnover of ECMand cellular homeostasis, leading to
slowly progressing chronic diseases such as inOA.
LRP-1 is widely expressed in different cell types
and controls extracellular levels of numerous biologically
active molecules to maintain tissue homeostasis (31). Cur-
rently, more than 50 ligands have been characterized,
including lipoproteins, ECM proteins, growth factors, cell
surface receptors, proteinases, proteinase inhibitors, and
secreted intracellular proteins (31). In cartilage, LRP-1
controls not only ECM-degrading proteinases but also the
Wnt/b-catenin signaling pathway by interacting with
Frizzled-1 (32) and connective tissue growth factor
(CCN2), and both regulate endochondral ossification and
articular cartilage regeneration (33), emphasizing the
Figure 6. Low-density lipoprotein receptor–related protein 1 (LRP-1)–mediated endocytic pathways in normal and osteoarthritic (OA) cartilage.
A, Secreted ADAMTS-5 and matrix metalloproteinase 13 (MMP-13) are largely endocytosed by LRP-1 in normal cartilage. Thus, their activities
in the extracellular milieu are limited. B, In OA cartilage, the ectodomain of LRP-1 is shed by ADAM-17 and MMP-14, resulting in impairment
of endocytic capacity of chondrocytes. Blocking of ADAM-17 and MMP-14 activities recovers the lost endocytic function of OA chondrocytes,
reduces cartilage matrix degradation, and restores cartilage homeostasis.
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importance of LRP-1 in skeletal development and in the
maintenance of cartilage homeostasis.
Thus, the impairment of LRP-1 function due to
increased shedding of the receptor is detrimental to
healthy cartilage, as demonstrated in the present study.
This is triggered by increased activity of ADAM-17 and
MMP-14, but their protein levels were not significantly
changed between healthy and OA cartilage (data not
shown), which suggests that the activation of these
enzymes is regulated posttranslationally. The additive but
not synergistic effect of anti–ADAM-17 and anti–MMP-
14 antibodies further suggests that these proteinases may
be activated by different mechanisms and act indepen-
dently as LRP-1 sheddases. In addition, MMP-14 and
ADAM-17 cleave a number of cell membrane proteins,
including growth factors, cytokines, cell adhesion mole-
cules, and mechanosensors (26,34). Therefore, their acti-
vation may also affect the integrity of other cell surface
molecules in cartilage as well as cellular behavior. We are
currently investigating how ADAM-17 and MMP-14 are
activated as well as their substrate selectivity in cartilage,
as these may indicate additional molecular mechanisms
for the development ofOA, particularly in the early stages.
Another notable finding of this study is that anti–
ADAM-17 and anti–MMP-14 antibodies reduced both
aggrecanolytic and collagenolytic activities of human OA
cartilage in culture, and this effect was due to restora-
tion of the lost LRP-1 function by blocking the LRP-1
sheddase activities of ADAM-17 and MMP-14 (Figure
6). These results suggest that inhibition of elevated LRP-
1 sheddase activities in OA cartilage may be an effective
way to prevent cartilage matrix degradation. Although
the systematic inhibition of ADAM-17 and MMP-14 as
OA therapy may be problematic, as these enzymes are
biologically important in the release of growth factors and
cell surface receptors in many cell types (27,34), local
administration of anti–ADAM-17 and anti–MMP-14
antibodies or small molecule inhibitors of ADAM-17 and
MMP-14 may be worth investigating as disease-modifying
OA drugs. This approach is an attractive option for OA
therapy, as the recovery of the lost endocytic function of
chondrocytes would help to maintain cartilage homeosta-
sis. We are currently testing whether this approach is ben-
eficial in early and advanced OA, using preclinical animal
models.
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